文献速递膀胱癌与上尿路尿路上皮癌

病理降期作为上尿路尿路上皮癌新辅助化疗开发的新终点指标

Pathological downstaging as a novel endpoint for the development of neoadjuvant chemotherapy for upper tract urothelial carcinoma.
PubMed 文献 · BJU Int · 2019-03-26

基于美国国家癌症数据库的高级别cN0M0上尿路尿路上皮癌患者,接受新辅助化疗后评估病理降期(pDS)与病理完全缓解(pCR)对总生存(OS)的预测价值。264例中72例(27%)达pDS、39例(15%)达pCR;多因素分析显示pDS与pCR均与OS相关,但含pDS模型判别力优于含pCR模型(C指数76.4 vs 72.7),在cT2-4亚组中结果一致。

要点

  • pDS定义为cT至pT至少降一期且pN0,包含pCR。
  • 264例中72例(27%)达pDS,39例(15%)达pCR。
  • 含pDS模型预测OS的C指数76.4,优于含pCR模型的72.7。

核心结论

  • 上尿路尿路上皮癌新辅助化疗后,pDS在预测总生存方面比pCR提供更多信息,但需前瞻性验证。

研究设计与样本

  • 回顾性查询美国国家癌症数据库,纳入接受新辅助化疗的高级别cN0M0上尿路尿路上皮癌患者264例。
  • pDS定义为cT至pT至少降一期且pN0(包含pCR);分别拟合含pDS或pCR的多因素Cox模型预测OS,并用Harrell C指数评估判别力。
  • 在cT2-4N0M0患者128例中重复分析。

主要发现

  • 264例中72例(27%)达pDS,39例(15%)达pCR。
  • 多因素分析中pDS与OS相关(HR 0.24,95%CI 0.13-0.45,P<0.001),pCR亦与OS相关(HR 0.37,95%CI 0.18-0.79,P=0.01)。
  • 含pDS模型判别力优于含pCR模型:C指数76.4 vs 72.7。
  • cT2-4亚组128例中,pDS(HR 0.19,95%CI 0.09-0.40,P<0.001)与pCR(HR 0.31,95%CI 0.11-0.85,P=0.023)均为OS预测因素,含pDS模型C指数75 vs 含pCR模型68.9。

临床怎么用

  • 作者认为,上述发现虽需前瞻性验证,但可帮助设计旨在优化化疗及其他全身治疗在该场景中应用的临床试验。

局限性

  • 原文结论指出这些发现需要前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate whether pathological downstaging (pDS) was more informative in predicting overall survival (OS) than pathological complete response (pCR) in patients treated with neoadjuvant chemotherapy (NAC) for upper tract urothelial carcinoma (UTUC). PATIENTS AND METHODS: The National Cancer Database was queried for patients with high-grade cN0M0 disease who had received NAC. pDS was defined as a decrease of at least one stage from cT to pT stage along with pN0, including pCR. A multivariable Cox model predicting OS was generated by fitting alternatively either pDS or pCR, and adjusted for potential confounders. The discrimination of the Cox models for predicting OS was evaluated using Harrell's C-index. The analyses were repeated in patients diagnosed as having cT2-4N0M0 disease. RESULTS: Among 264 patients meeting the inclusion criteria, 72 (27%) and 39 (15%) achieved pDS and pCR, respectively. On multivariable analysis, both pDS (hazard ratio [HR] 0.24, 95% confidence interval [CI] 0.13, 0.45; P < 0.001) and pCR (HR 0.37, 95% CI 0.18, 0.79; P = 0.01) were associated with OS. The model including pDS achieved better discrimination with respect to the model including pCR: C-index 76.4 vs 72.7, respectively. In the 128 patients diagnosed with cT2-4 disease, both pDS (HR 0.19, 95% CI 0.09, 0.40; P < 0.001) and pCR (HR 0.31, 95% CI 0.11, 0.85; P = 0.023) were confirmed as predictors of OS. The model including pDS was confirmed to discriminate better than the model including pCR: C-index 75 vs 68.9, respectively. CONCLUSION: The study showed that pDS after NAC for UTUC was more informative than pCR when predicting OS. These findings, although requiring prospective validation, can aid in the design of clinical trials seeking to refine the use of chemotherapy and other systemic therapies in this setting.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Martini A, Daza J, Poltiyelova E, et al. Pathological downstaging as a novel endpoint for the development of neoadjuvant chemotherapy for upper tract urothelial carcinoma. BJU Int. 2019. PMID: 30801918. doi:10.1111/bju.14719

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。